Lupin shares gained 2.8% after the US Food and Drug Administration approved its Risperidone extended-release injectable for schizophrenia and bipolar I disorder, with 180-day CGT exclusivity. Developed via unit Nanomi's LAI tech, the drug is bioequivalent to Janssen's Risperdal Consta. US sales for Risperidone LAI stood at $190 million (MAT July 2025). Lupin stock is down 17% YTD.